Citations

Clear

4610 citation(s) found for "Lu, Brian".

Mechanosensitive Channels in Lung Health and Disease
Migulina, Nataliya , Kelley, Brian M. , Zhang, Emily , Kelley, Brian, Pabelick, Christina M. , Prakash, Y. S. , Vogel, Elizabeth R.

Mayo Clinic

Comprehensive Physiology | April 3, 2025 | Volume: 13 | Issue: 4 | Pages: 5157-5178

10.1002/j.2040-4603.2023.tb00284.x Get It

Abstract The lung is an inherently mechanosensitive organ, where cells of the airway and parenchyma experience a range of mechanical forces throughout life including shear, stretch, and compression, in both health and disease. In this regard, pediatric and adult lung diseases such as wheezing and asthma, bronchopulmonary dysplasia (BPD), chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis (PF) all involve macroscopic and cellular changes to the mechanical properties of the bronchial airways and/or parenchyma to varying extents. Accordingly, understanding how mechanical forces are sensed in the lung, and the responses of cells and tissues in the context of normal development and health versus disease conditions becomes highly relevant. There is increasing recognition that transduction of mechanical forces into cellular responses involves a number of channels, some of which are inherently mechanosensitive. Such channels trigger mechanotransduction pathways that may further mediate cellular remodeling, inflammation, and other pathophysiologic mechanisms in response to stretch, stiffness, and inflammatory cascades. Two particularly important channel families have emerged in pulmonary pathophysiology: the transient receptor potential vanilloid family with focus on member TRPV4 and the recently identified Piezo (PZ) channels. Here, we explore current understanding of the contributions of TRPV4 and PZ channels in lung health and disease states, focusing on the interactions between these mechanosensitive channels and their local environment including immune cells, the extracellular matrix, and cellular cytoskeletal elements. We further discuss potential areas for future research to better understand the impact of mechanical channels on pulmonary health and disease. © 2023 American Physiological Society. Compr Physiol 13:5157‐5178, 2023.
Why Consider Aspirin for the Treatment of Vestibular Schwannoma? A Brief Review and Randomized, Double‐Blind, Placebo‐Controlled Study Proposal
Welling, D. Bradley , Neff, Brian A., Telischi, Fred F. , Patel, Neil , Stanković, Konstantina M.

Mayo Clinic

Laryngoscope Investigative Otolaryngology | April 2, 2025 | Volume: 10 | Issue: 2 | Pages: No page available

10.1002/lio2.70121 | PMID 40171318 Get It

ABSTRACTObjectiveThe primary objective of this study is to review the evidence for aspirin use to prevent the growth of vestibular schwannomas (VS) and to propose a prospective trial to determine the progression‐free survival of VS patients after up to 42 months of treatment with aspirin. Secondary study objectives are to determine the effect of aspirin on VS growth, hearing function, serum biomarker levels, and the quality of life, as well as to determine the tolerability of aspirin treatment and whether serum biomarker and salicylate levels predict the response to aspirin.Study DesignLiterature review.SettingSix academic and private medical centers.MethodsReview of recent English literature regarding prophylactic aspirin use for VS.ResultsThe retrospective reviews on the utility of aspirin to prevent VS growth are inconclusive. Eighty‐four patients have been enrolled in a prospective double‐blinded, placebo‐controlled trial thus far to determine the effect of aspirin on VS.ConclusionsCompletion of a robust study design is necessary. The current aspirin dose has been well tolerated, with minimal adverse events to date.Level of EvidenceReview of retrospective studies: Level 4; Proposed randomized, placebo‐controlled, double‐blinded clinical trial: Level 2.
Intracranial stimulation for pediatric refractory epilepsy: A single institutional experience using evolving therapies
Singh, Rohin , Bauman, Megan M. J. , Islam, Karimul , Kerezoudis, Panagiotis , Grewal, Sanjeet S. , Parker, Jonathon J. , Gompel, Jamie J. Van , Miller, Kai J. , Lundstrom, Brian N. , Starnes, Keith , Van Gompel, Jamie J , Grewal, Sanjeet , Lundstrom, Brian Nils , Bauman, Megan , Starnes, Donnie Keith , Singh, Rohin , Islam, Karimul

Mayo Clinic

Epilepsia Open | April 2, 2025 | Volume: 10 | Issue: 3 | Pages: 694-704

10.1002/epi4.70006 | PMID 40167570 Get It

AbstractObjectiveNeuromodulation for pediatric refractory epilepsy (PRE) is preferred when the seizure onset zone is not amenable to surgical resection, due to multifocal onset or involvement of eloquent cortex. Given its rapidly evolving landscape, we describe our institutional experience with neurostimulation therapies including deep brain stimulation (DBS) of the anterior nucleus (DBS‐ANT), the centromedian nucleus (DBS‐CM), responsive neurostimulation (RNS), and chronic subthreshold stimulation (CSS) to treat PRE.MethodsA retrospective chart review was conducted to identify pediatric patients (≤18 years of age) who presented to our institution with PRE. Patients were included who had at least 1 year of follow‐up after neurostimulation was started. Patients with ≥50% seizure frequency reduction at last follow‐up compared to baseline were classified as responders.ResultsA total of 35 patients (21 females) were included in the series. Nine patients underwent DBS‐ANT, 9 underwent DBS‐CM (+ ANT in 7 patients), 5 underwent RNS, and 12 underwent CSS. The median age at seizure onset and surgery was 8 and 16 years, respectively. Structural lesions were the most common etiology of epilepsy (54%). Eighteen patients had prior interventions and 13 received invasive EEG. Post‐operative complications following neurostimulation implantation were noted in three patients (9%). However, no permanent deficits were noted. Median follow‐up time was 46 months (range 13–162 months). Twenty‐three patients (59%) were responders (3/9 DBS‐ANT; 7/9 DBS‐CM; 4/5 RNS; 9/12 CSS). Further, median seizure reduction was 25% (DBS‐ANT), 89% (DBS‐CM), 87% (RNS), and 88% (CSS) across the cohort. Six patients (17%) had improved subjective neurocognitive outcomes while the other 29 had stable neurocognitive outcomes.SignificanceDBS, RNS, and CSS are safe and effective options for PRE. An understanding of treatment approaches can optimize results by tailoring therapy to individual patients.Plain Language SummaryThis study investigates the use of various neurostimulation therapies for treating pediatric refractory epilepsy (PRE) including deep brain stimulation (DBS), responsive neurostimulation (RNS), and chronic subthreshold stimulation (CSS). Overall, neuromodulation was found to be effective in reducing seizures in most patients, with 59% of patients showing at least a 50% reduction in seizure frequency. Additionally, the treatments were generally safe, with few complications and no instances of permanent deficits.
Long-Term Patient-Reported Bowel and Urinary Quality of Life in Patients Treated with Intensity-Modulated Radiotherapy Versus Intensity-Modulated Proton Therapy for Localized Prostate Cancer
Gergelis, Kimberly R. , Bai, Miao , Ma, Jiasen , Stish, Bradley J. , Davis, Brian J. , Pisansky, Thomas M. , Whitaker, Thomas J. , Choo, Richard , Davis, Brian J , Bai, Miao , Routman, David M.

Mayo Clinic

Current Oncology | April 2, 2025 | Volume: 32 | Issue: 4 | Pages: 212

10.3390/curroncol32040212 | PMID 40277768 Get It

Purpose: This study aimed to compare long-term patient-reported outcomes in bowel and urinary domains between intensity-modulated radiotherapy (IMRT) and intensity-modulated proton therapy (IMPT) for localized prostate cancer. Methods and Materials: Patients with clinical T1–T2 prostate cancer receiving IMRT or IMPT at a tertiary cancer center from 2015–2018 were analyzed to determine the changes in the prospectively collected bowel function (BF), urinary irritative/obstructive symptoms (UO), and urinary incontinence (UI) domains of EPIC-26. The mean changes in EPIC-26 scores were evaluated from pretreatment to 24 months post-radiotherapy for each modality. A score change >50% of the baseline standard deviation was considered a clinically meaningful change. Results: A total of 82 patients treated with IMRT (52.2%) and 56 patients treated with IMPT (53.3%) completed the questionnaire at baseline and 24 months post-RT. There were no baseline differences in domain scores between treatment modalities. At 24 months post-radiotherapy, there was a significant and clinically meaningful decline in the BF mean score in the IMRT cohort (−4.52 (range −50, 29.17), p = 0.003), whereas the decline in BF score did not reach clinical relevance or significance (−1.88 (range −37.5, 50), p = 0.046) when accounting for the Bonferroni adjustment in the IMPT cohort. A higher proportion of patients treated with IMRT had a clinically relevant reduction in BF when compared with IMPT (47.37% vs. 25.93%, p = 0.017). The mean changes in the UI and UO scores of the IMRT and IMPT cohorts were neither statically significant nor clinically relevant. Conclusions: IMPT leads to a smaller decrease in BF than IMRT at 24 months post-RT, while there was no differential effect on UO and UI.
Postoperative Treatment Regimens in Patients With Native Valve Endocarditis due to Staphylococcus aureus Who Undergo Valve Replacement or Repair
Katragadda, Silpita , Baddour, Larry M. , Quintero-Martinez, Juan Andres , Bois, Melanie C. , O’Horo, John C. , Lahr, Brian D. , DeSimone, Daniel C. , Chesdachai, Supavit , Quintero-Martinez, Juan A , Bois, Melanie C , O'Horo, John C , Lahr, Brian , DeSimone, Daniel C , Baddour, Larry , Chesdachai, Supavit

Mayo Clinic

Open Forum Infectious Diseases | March 30, 2025 | Volume: 12 | Issue: 4 | Pages: No page available

10.1093/ofid/ofaf179 | PMID 40207048 Get It

Abstract Background There remains a lack of consensus regarding the postoperative treatment regimen in patients with native valve Staphylococcus aureus infective endocarditis who undergo surgical valve replacement or repair. Methods We conducted a multicenter retrospective review of patients with S aureus native valve endocarditis who underwent surgical valve replacement or repair at Mayo Clinic Enterprise (Minnesota, Florida, Arizona, and Mayo Clinic Health Systems) between 1 January 2012 and 31 December 2022. Postoperative treatment regimens were classified as either monotherapy with a methicillin-sensitive or methicillin-resistant S aureus active agent or combination therapy that included rifampin and/or gentamicin with either active agent. Results Of the 339 patients diagnosed with S aureus native valve endocarditis, 61 underwent surgical valve replacement or repair within the initial 6 weeks of antimicrobial therapy. A total of 12 (20.2%) patients died during the 1-year follow-up period. Between patients postoperatively treated with monotherapy (n = 33) and combination therapy (n = 28), a propensity score–weighted analysis revealed that combination therapy was associated with increased risk of 1-year mortality (P = .039), 6-month relapse (P = .016), and treatment-related adverse events (P < .001). Conclusions Among patients treated for native valve infective endocarditis caused by S aureus after valvular surgical intervention, all study outcomes—adverse events and drug-drug interactions, 6-month infective endocarditis relapse, and 1-year mortality—were higher in the combination therapy group than the monotherapy group.
A Descriptive 5‐Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA: A Multicenter Study of 390 Disease Episodes From 2017 to 2021
Jacobs, Jeremy W. , Adkins, Brian D. , Stanek, C , Stephens, Laura D. , Daou, Laetitia , Siniard, Rance C. , Wallace, Lisa R., Duque, Miriam Andrea, Wu, Yanyun , Aljuboori, Omar , Harrington, Thomas J., Byrnes, Diana M. , Eichbaum, Quentin , Klapper, Ellen, Klein, Monica S., Alkhateb, Rahaf, Powers, Amy, Webb, Christopher B. , Yates, Sean G. , Bloch, Evan M. , Adkins, Brian D. , Booth, Garrett , Stanek, Caroline G , Grossman, Brenda J , Stephens, Laura , Crowe, Elizabeth P , Marques, Marisa B , Yamada, Chisa , Juskewitch, Justin E , Perez-Alvarez, Ingrid , Parsons, Meredith G , Schlueter, Annette J , Tormey, Christopher A , Yates, Sean G , Bloch, Evan M , Raval, Jay S , Jacobs, Jeremy W , Adkins, Brian David , Adkins, Brian D. , Booth, Garrett S. , Allen, Elizabeth S. , Grossman, Brenda J. , Marques, Marisa B. , Yamada, Chisa , Villalba, Cristina A. Figueroa , Juskewitch, Justin E. , Aldarweesh, Fatima , Parsons, Meredith G , Schlueter, Annette J. , Tormey, Christopher A. , Wheeler, Allison P. , Raval, Jay S.

Mayo Clinic

Journal of Clinical Apheresis | March 30, 2025 | Volume: 40 | Issue: 2 | Pages: No page available

10.1002/jca.70017 | PMID 40145682 Get It

ABSTRACTImmune thrombotic thrombocytopenic purpura (iTTP) is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and microvascular occlusion secondary to acquired ADAMTS13 deficiency. Contemporary data regarding iTTP treatment practices in the US, including the use of caplacizumab, are lacking. We aimed to characterize the demographics and therapies, including medications and apheresis practices, in patients with iTTP in the US. We retrospectively analyzed iTTP cases at 15 sites in the US that provide comprehensive care for patients with iTTP. The time‐period assessed was from January 1, 2017 to December 31, 2021. Our primary objective was to analyze data by iTTP episode, inclusive of initial episodes and relapses. A total of 390 iTTP episodes were reported for 280 unique individuals (187 females, 93 males). Thirty‐day mortality was 3.7% (14/374), and 6‐month mortality was 7.4% (27/367). TPE details were reported for 343 episodes, among which 261 underwent at least one procedure (median 6, IQR 3–11). Among the 261 episodes with at least one therapeutic plasma exchange (TPE) performed, 82.0% (214/261) used only plasma. Caplacizumab was used either alone or in combination with other agents in 43 (11.0%) episodes. Management strategies for iTTP remain varied across centers in the US, with a variety of combinations for TPE replacement fluids and therapeutic agents, as well as limited use of caplacizumab. Further research and standardization of treatment regimens may further reduce mortality in this condition.
Diagnostic Cystoscopic Findings: A Primer for Urogynecology
Narayanamoorthy, S., Gebhart, John B. , Linder, Brian J.

Mayo Clinic

Obstetrics & Gynecology | March 28, 2025 | Volume: 145 | Issue: 5S | Pages: 47S-47S

10.1097/aog.0000000000005851.75 Get It

Practical Anemia Bundle and Hemoglobin Recovery in Critical Illness
Hanson, Andrew C. , Fortune, Emma , Flaby, Gerald W., Schulte, Phillip J. , Hazelton, Valerie M., Beam, William B. , Anderson, Brenda, Karon, Brad S. , Kor, Daryl J. , Johnson, Matthew L. , Beam, W Brian, Charnin, Jonathan E. , Anderson, Brenda K, Karon, Brad, Warner, Matthew A. , Go, Ronald S. , Cheville, Andrea , Gajic, Ognjen

Mayo Clinic

JAMA Network Open | March 28, 2025 | Volume: 8 | Issue: 3 | Pages: e252353

10.1001/jamanetworkopen.2025.2353 | PMID 40152861 Get It

Importance Anemia is a common complication of surgery and acute illness that is associated with adverse clinical outcomes. The role of anemia prevention and treatment strategies in this setting remains unclear. Objective To evaluate the effect of a multifaceted anemia management bundle vs standard care on posthospitalization hemoglobin recovery and multidimensional functional outcomes in survivors of acute illness. Design, Setting, and Participants This parallel group randomized clinical trial, known as the Practical Anemia Bundle for Sustained Blood Recovery, was conducted at postsurgical and medical intensive care units at a large US medical center. Critically ill patients (aged ≥18 years) with moderate to severe anemia (hemoglobin concentration <10 g/dL) were enrolled between March 2022 and November 2023. Participants were randomly assigned 1:1 to the intervention or standard care group. Intention-to-treat analyses were performed between July 2024 and January 2025. Intervention The intervention bundle was delivered throughout the duration of hospitalization and included optimized phlebotomy practices, clinical decision support, and pharmacological anemia treatment with intravenous iron. Main Outcomes and Measures The primary outcome was the mean difference in hemoglobin concentration at 1 month after hospital discharge. Results A total of 100 patients (median [IQR] age, 68 [61-72] years; 57 men [57.0%]; 65 [65.0%] with postsurgical admission to the intensive care unit) were enrolled during acute illness. Forty-nine patients (49.0%) were assigned to receive the intervention, and 51 (51.0%) were assigned to receive standard care. Hemoglobin concentration at 1 month after discharge was greater in patients receiving the intervention vs standard care (median [IQR], 12.2 [11.8-13.0] g/dL vs 11.5 [10.2-12.6] g/dL; adjusted mean difference, 0.69 [95% CI, 0.13-1.20] g/dL; P = .02). Conclusions and Relevance This randomized clinical trial found that a multifaceted anemia prevention and treatment bundle was feasible, was well tolerated, and improved posthospitalization hemoglobin concentrations up to 3 months in critically ill adults. These findings can inform the design of future trials. Trial Registration ClinicalTrials.gov Identifier: NCT05167734
BIO25-027: Addressing Early Diagnosis Challenges: Utilizing C the Signs Clinical Decision Support Platform for Pancreatic Cancer Risk Assessment
Raoof, Sana , Dadhania, Seema , Herrick, Brian, Bakshi, Bea, Payling, Miles, Patel, Tushar

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 28, 2025 | Volume: 23 | Issue: 3.5 | Pages: No page available

10.6004/jnccn.2024.7196 Get It